Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines: Activation Lethality [Yahoo! Finance]
IDEAYA Biosciences, Inc. (IDYA)
Last ideaya biosciences, inc. earnings: 3/24 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Delphia is leveraging its activation lethality platform to develop highly differentiated, first-in-class targeted cancer medicines with the potential for significant anti-tumor activity and more durable patient benefit Founded by industry leading oncology drug developers Kevin Marks, Bill Sellers and Mike Dillon; $67 million Series A financing led by GV, Nextech Invest, Polaris Innovation Fund and Alexandria Venture Investments CAMBRIDGE, Mass., May 02, 2024 BUSINESS WIRE )--Delphia Therapeutics, Inc. (Delphia), announced its launch today to pioneer a new area of cancer biology – activation lethality – which targets cancer's surprising vulnerability to oncogene overactivation. Leveraging this next-generation approach, Delphia is advancing highly differentiated first-in-class targeted cancer medicines with the potential for significant anti-tumor activity and more durable patient benefit across multiple prevalent cancer types. Delphia completed a $67 million Series A financing led
Show less
Read more
Impact Snapshot
Event Time:
IDYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDYA alerts
High impacting IDEAYA Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
IDYA
News
- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $53.00 to $46.00. They now have a "buy" rating on the stock.MarketBeat
- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $52.00 price target on the stock.MarketBeat
- IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business UpdatePR Newswire
- IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations EventPR Newswire
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)PR Newswire
IDYA
Sec Filings
- 5/16/24 - Form 4
- 5/14/24 - Form 144
- 5/7/24 - Form 10-Q
- IDYA's page on the SEC website